Skip to main content

Advertisement

Fig. 4 | Arthritis Research & Therapy

Fig. 4

From: In vitro and in vivo assessment of the proresolutive and antiresorptive actions of resolvin D1: relevance to arthritis

Fig. 4

RvD1 treatment improves RA clinical endpoints as well as synovium and bone changes in arthritic mice. Arthritis was induced by i.p. injection of arthritogenic cocktail of five monoclonal anti-type II collagen monoclonal antibodies (mAb) on day 1, followed by i.p. injection of 50 μg LPS on day 4, as described in the “Materials and methods” section. Over the course of the experiment, and for each of the experimental groups (non-immunized control mice, CAIA mice immunized with type II collagen antibody and treated with vehicle, and mice immunized with type II collagen and treated with RvD1 (100, 500, 1000 ng/day) at day 1 or with 1000 ng/ml at day 4, clinical score was attributed by two investigators blinded to groups on a scale of 0–4 for each paw, for a maximum of 16 for all four paws, as described in the “Materials and methods” section (a). Hind paw thickness was measured using a caliper and expressed as thickness change from baseline (b). Weight evolution was assessed and expressed as percentage of weight loss from baseline (c). Data are means ± SEM for n = 6, and one-way ANOVA was performed to compare the results. *p < 0.05 and **p < 0.01 compared to RA group. Cell proliferation in synovial membrane and TRAP staining in bone were performed as described in the “Materials and methods” section (d)

Back to article page